Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7885345 | 0.89 | SMN1; SMN2 (0.44) | LTA4HCYP3A4CYP1A2CYP2D6HSD11B1 | |
| SCHEMBL22361384 | 0.82 | KDM2B (0.41) | LTA4H | |
| SCHEMBL28941581 | 0.82 | CHRM5 (0.48) | LTA4HSMN1; SMN2ACHE | |
| SCHEMBL28750104 | 0.82 | CHRM5 (0.44) | LTA4HCCR2KCNH2SMN1; SMN2ACHE | |
| SCHEMBL2204349 | 0.82 | LTA4H (0.43) | LTA4HCYP2D6BCHEACHE | |
| SCHEMBL15142809 | 0.81 | SMN1; SMN2 (0.45) | LTA4HCYP2D6SMN1; SMN2 | |
| SCHEMBL2607208 | 0.81 | SMN1; SMN2 (0.45) | LTA4HCYP2D6SMN1; SMN2 | |
| SCHEMBL15142807 | 0.81 | SMN1; SMN2 (0.45) | LTA4HCYP2D6SMN1; SMN2 | |
| SCHEMBL27564415 | 0.81 | CHRM5 (0.52) | LTA4HSMN1; SMN2ACHE | |
| SCHEMBL3298176 | 0.81 | SLC6A12 (0.42) | HSD11B1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20200369648-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-11-26 | — | — | US | disclosed |
| US-10836750-B1 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-11-17 | — | — | US | disclosed |
| EP-0983269-A4 | PROCESS FOR PREPARING HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-0983269-A1 | PROCESS FOR PREPARING HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998054179-A1 | PROCESS FOR PREPARING HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | LTA4H 2388/4885CYP3A4 1291/4885CYP1A2 1595/4885 |
| US-20200369648-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | LTA4H 2020/4885CYP3A4 3293/4885CYP1A2 2151/4885 |
| US-10836750-B1 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | LTA4H 2020/4885CYP3A4 3293/4885CYP1A2 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.